As such, PPARα/β/γGPR40 pan-agonist RLA8A was designed to ameliorate non-alcoholic steatohepatitis and fibrosis in mice [122], leaving the answer open if this quadruple targeting may also counteract cancer development. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.